Please assess the completion status of the following clinical trial:

Trial Title: A Study of GW856553X For the Treatment of Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female = 18 years of age and \< 60 years,~* routine laboratory results within normal ranges,~* Body Mass Index within the range 18.5-35.0 kg/m2 inclusive.~* Subject must have had at least one previous major depressive episode with a diagnosis of MDD in his/her history, and had a successful pharmacological treatment of that episode, and is currently experiencing a recurrence of MDD presently un-medicated.~* Subjects must met the diagnosis of an episode of Major Depressive Disorder in the past 12 weeks but not greater than 24 months.~Exclusion Criteria:~* The subject has any history of liver disease.~* The subject has significant cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.~* The subject has a history of autoimmune diseases.~* The subject has any active infectious diseases, including active tuberculosis or a history of active tuberculosis.~* The subject has a history of malignancy, except for surgically cured basal cell carcinoma or females with cured cervical carcinoma (\> 2 yrs prior).~* The subject has a history of HIV or other immunosuppressive disease.~* The subject has uncontrolled diabetes.~* The subject is pregnant or nursing.~* Subject has no contact with an adult on a daily basis (i.e., subjects who are not living with at least one other adult or subjects who do not have an adult who contacts them on a daily basis).~* Subject has initiated psychotherapy within three months prior to the Screening visit, or plans to initiate psychotherapy during the trial.~* Subject has received electroconvulsive therapy or transcranial magnetic stimulation or vagal nerve stimulation within the six months prior to the Screening.~* The subject is currently receiving a chronic biological or pharmacologic anti-inflammatory therapy; interferon therapy at any dose or did receive them within 6 months prior randomisation.~* Subjects who have donated a unit of blood within the previous month or intends to donate in the month after completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): GW856553X 7.5mg BID for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match, BID, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).